MEI Pharma Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Jay File

Chief executive officer

US$655.7k

Total compensation

CEO salary percentage	68.6%
CEO tenure	1.3yrs
CEO ownership	n/a
Management average tenure	2.1yrs
Board average tenure	3.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jay File's remuneration changed compared to MEI Pharma's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-US$47m
Jun 30 2024	US$656k	US$450k	US$18m

Compensation vs Market: Jay's total compensation ($USD655.65K) is above average for companies of similar size in the UK market ($USD357.75K).

Compensation vs Earnings: Insufficient data to compare Jay's compensation with company performance.

CEO

Jay File (54 yo)

1.3yrs

Tenure

US$655,650

Compensation

Mr. Justin J. File, also known as Jay, serves as CFO & Corporate Secretary at MEI Pharma, Inc. since August 01, 2023 and serves as its Acting Chief Executive Officer from August 01, 2024. He had been an Ex...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Justin File	Acting CEO	1.3yrs	US$655.65k	no data
Yomara Gomez-Naiden	Senior Vice President of Operations & Quality	1.3yrs	no data	no data
Nicole Iida	Vice President of Legal Affairs	1.8yrs	no data	no data
Anne Frese	Chief People Officer	2.4yrs	no data	no data
Robert Mass	Strategic Advisor	13.4yrs	US$755.98k	no data
David Walsey	Senior Vice President of Corporate Affairs	3.5yrs	no data	no data

2.1yrs

Average Tenure

Experienced Management: 0JW9's management team is considered experienced (2.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Frederick Driscoll	Independent Chairperson	6.8yrs	US$117.20k	0.028% $ 5.3k
Nicholas Glover	Independent Non-Executive Director	11.4yrs	US$122.78k	0% $ 0
Thomas Reynolds	Independent Non-Executive Director	11.8yrs	US$115.28k	0.0075% $ 1.4k
Steven Wood	Independent Non-Executive Director	1.1yrs	US$112.40k	0.14% $ 26.3k
James Flynn	Independent Director	less than a year	US$114.07k	0.12% $ 22.2k
Taheer Datoo	Director	less than a year	US$68.06k	no data

3.9yrs

Average Tenure

49yo

Average Age

Experienced Board: 0JW9's board of directors are considered experienced (3.9 years average tenure).

MEI Pharma Management

Management criteria checks 2/4

Key information

Recent management updates

MEI Pharma, Inc. Announces Management Changes

MEI Pharma, Inc., Annual General Meeting, Dec 18, 2023

MEI Pharma, Inc. Announces Board Changes

MEI Pharma, Inc. Announces Chief Financial Officer Changes, Effective as of August 1, 2023

MEI Pharma, Inc. Announces Change of CFO, Effective No Later Than September 1, 2023

MEI Pharma, Inc. Announces Executive Changes

Recent updates

MEI Pharma, Inc. Announces Management Changes

MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data

MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

MEI Pharma, Inc. Reports Update from Clinical Study Evaluating Oral Cdk9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

MEI Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $10.3 million.

MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib At ASH2023

MEI Pharma, Inc., Annual General Meeting, Dec 18, 2023

MEI Pharma, Inc. Declares Special Cash Dividend of Common Stock, Payable on December 6, 2023

MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023

MEI Pharma, Inc. Announces Board Changes

MEI Pharma, Inc. to Report Fiscal Year 2023 Results on Sep 26, 2023

MEI Pharma, Inc. Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN) in Patients with Previously Treated Metastatic Colorectal Cancer

MEI Pharma, Inc. Announces Chief Financial Officer Changes, Effective as of August 1, 2023

MEI Pharma, Inc. Announces Change of CFO, Effective No Later Than September 1, 2023

MEI Pharma, Inc. Announces Executive Changes

Funicular Fund, LP, managed by Cable Car Capital, LLC, Anson Funds Management LP, Anson Advisors Inc., Anson Management GP LLC, Bruce R. Winson, Amin Nathoo and Moez Kassam submitted a proposal to acquire remaining 85.2% stake in MEI Pharma, Inc. (NasdaqCM:MEIP) for $45.4 million.

Funicular Fund, LP, managed by Cable Car Capital, LLC, Anson Funds Management LP, Anson Advisors Inc., Anson Management GP LLC, Bruce R. Winson, Amin Nathoo and Moez Kassam submitted a proposal to acquire remaining 85.2% stake in MEI Pharma, Inc. (NasdaqCM:MEIP) for $45.4 million.

MEI Pharma, Inc Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies

Third quarter 2023 earnings released: US$2.32 loss per share (vs US$1.31 loss in 3Q 2022)

Insufficient new directors

Insufficient new directors

MEI Pharma, Inc. Initiates Realignment of Its Clinical Development Efforts

Kyowa Kirin Co., Ltd. and MEI Pharma, Inc. Announce Topline Data from Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-Cell Non-Hodgkin’s Lymphoma in Japan

MEI Pharma, Inc. Announces Not Stand for Re-Election of Directors

MEI Pharma, Inc., Annual General Meeting, Dec 06, 2022

MEI Pharma, Inc. Announces Not Stand for Re-Election of Cheryl L. Cohen as Member of the Board of Directors

Mei Pharma Announces Changes to Board of Directors

MEI Pharma, Inc. Announces Board Changes

Full year 2022 earnings released: US$0.44 loss per share (vs US$0.37 loss in FY 2021)

MEI Pharma, Inc. to Report Fiscal Year 2022 Results on Sep 08, 2022

MEI Pharma and Kyowa Kirin Announce Publication in the Lancet Oncology of Data from Phase 1B Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-Cell Malignancy

MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

MEI Pharma, Inc. announced delayed 10-Q filing

MEI Pharma Receives Non-Compliance Notice from Nasdaq

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

MEI Pharma, Inc. Announces New Key Executive Appointments

No longer forecast to breakeven

MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. Announce Data from Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma

Independent Non Executive Director Kevan Clemens has left the company

First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.019 loss in 1Q 2021)

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Full year 2021 earnings released: US$0.45 loss per share (vs US$0.51 loss in FY 2020)

MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. Announce First Patient Dosed in the Phase 3 Coastal Study Evaluating Zandelisib Plus Rituximab in Relapsed or Refractory Indolent Non Hodgkin's B-Cell Lymphoma

Forecast to breakeven in 2024

Forecast to breakeven in 2024

MEI Pharma, Inc.(NasdaqCM:MEIP) dropped from Russell 3000E Value Index

MEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific Program

MEI Pharma and Kyowa Kirin Announce First Patient with Marginal Zone Lymphoma Dosed in Expanded Global Phase 2 TIDAL Study Evaluating Zandelisib

MEI Pharma, Inc. and Kyowa Kirin Announce New Clinical Data on Zandelisib At American Society of Clinical Oncology Annual Meeting 2021

MEI Pharma and Kyowa Kirin to Present Clinical Data from Phase 1b Study of Zandelisib in Combination with Zanubrutinib at the European Hematology Association 2021 Virtual Congress

Third quarter 2021 earnings released: US$0.28 loss per share (vs US$0.041 loss in 3Q 2020)

Independent Non-Executive Director recently sold US$101k worth of stock

Second quarter 2021 earnings released: US$0.10 loss per share (vs US$0.26 loss in 2Q 2020)

Revenue beats expectations

MEI Pharma, Inc. Announces Expansion of Phase 1b Study Evaluating Zandelisib and Clinical Pipeline Update

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age